Search Results

Micron Solutions, Inc., through its wholly-owned subsidiary, Micron Products, Inc. announced the Board’s approval of a proposal to effect a 1-for-1,000 reverse stock split of the Company’s Common Stock, followed immediately by a 1,000 to 1 forward stock split for the Company’s Common Stock, which Stock Splits will be enacted through the filing of amendments to the Company’s Certificate of Incorporation with the Secretary of State of the State of Delaware.

Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the transport, storage, and administration of drugs and vaccines, today announced the publication of its positive Measles and Rubella (MR) Phase 1/2 trial data in The Lancet Medical Journal.

Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the transport, storage, and administration of drugs and vaccines, announced the appointment of global public health pioneer, Dr. Seth Berkley, as scientific advisor to the CEO.

Micron Biomedical announced a $23.6 million grant from the Bill & Melinda Gates Foundation that will fund mass production of needle-free vaccines.

Micron Solutions, Inc. (OTCQB: MICR) (the “Company”) announced financial results for its fourth quarter and fiscal year ended December 31, 2022.

Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the administration, transport and storage of drugs and vaccines, today announced the appointment of drug delivery and healthcare innovation veteran, Brian Bernick, MD, as Chairman of the company’s Board of Directors.

Surmodics, Inc. announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective June 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Surmodics Pounce™ and Pounce™ Venous Thrombectomy Systems.

Micron Solutions, Inc. (OTCQB: MICR) (the “Company”) announced financial results for its third quarter ended September 30, 2022.

Product Creation Studio, a premier provider of engineering and design services, is excited to announce a new partnership with PatchClamp Medtech Inc.